Aptamer mediated siRNA delivery
Top Cited Papers
Open Access
- 31 May 2006
- journal article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 34 (10), e73
- https://doi.org/10.1093/nar/gkl388
Abstract
Nucleic acids that bind to cells and are subsequently internalized could prove to be novel delivery reagents. An anti-prostate specific membrane antigen aptamer that has previously been shown to bind to prostate tumor cells was coupled to siRNAs via a modular streptavidin bridge. The resulting conjugates could be simply added onto cells without any further preparation, and were taken up within 30 min. The siRNA-mediated inhibition of gene expression was as efficient as observed with conventional lipid-based reagents, and was dependent upon conjugation to the aptamer. These results suggest new venues for the therapeutic delivery of siRNAs and for the development of reagents that can be used to probe cellular physiology.Keywords
This publication has 35 references indexed in Scilit:
- Induction of the interferon response by siRNA is cell type– and duplex length–dependentRNA, 2006
- Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.2003
- RNAi in Human CellsMolecular Cell, 2002
- Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.2002
- Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cellsNature, 2001
- Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor MicrovesselsJournal of Biological Chemistry, 2001
- Reduced antibody response to streptavidin through site‐directed mutagenesisProtein Science, 2001
- Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophinBrain Research, 2001
- Escort aptamers: a delivery service for diagnosis and therapyJournal of Clinical Investigation, 2000
- Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier.1999